The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial.
WHITE PLAINS, N.Y., Dec. 3 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Memgen, LLC jointly announce the beginning of a new clinical trial of ISF35, a cancer vaccine, at the University of California, San Diego (UCSD). LLS is collaborating on this trial in the hopes...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH.
-- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies.
- Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral sessions at ASH - Exjade results at ASH to show benefits for chronically transfused patients by significantly reducing toxic iron that can damage key organs...

Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH.
SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008, at 4:00 p.m. PST, to discuss the results of Rigel's Phase 2 clinical trial of R788,...

Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting.
BETHESDA, Md., Dec. 3 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference call on, Monday, December 8, 2008, at 2:00 p.m. Eastern Time (8:00 p.m. Central European Time) to discuss...

Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting.
Company Introduces New Trade Name Onrigin(TM) for Laromustine NEW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (BULLETIN BOARD: VION) today made several announcements related to events in connection with the 50th American Society of Hematology Annual Meeting at the Moscone Center in San Francisco from...

Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference.
PRINCETON, N.J., Nov. 25 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York and the 2008 Mid-Atlantic Capital Conference in Philadelphia. Mr. Jackson will provide a corporate overview and an...

MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology.
'A Highly Efficient, Clinical Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity' GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces that Joseph C. Fratantoni, MD, Vice President Medical...

Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference.
CARLSBAD, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Genoptix, Inc. , a specialized laboratory services provider, today announced the Company's participation at the RBC Capital Markets 2008 Healthcare Conference scheduled to take place at the Westin New York Hotel at Times Square on December 10-11, 2008. Sam Riccitelli, COO...

Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting.
MONTREAL, Nov. 25 /PRNewswire/ -- Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral presentation at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, on December...